Home › Research › Prevention and risk
Exercise Prescription in Arrhythmogenic Cardiomyopathy: Finding the Right Balance Between Risks and Benefits
Lorenzo‐Lupo Dei, Jennie Han, Silvio Romano, Luigi Sciarra, Angeliki Asimaki, Michael Papadakis, Sanjay Sharma, Gherardo Finocchiaro. Journal of the American Heart Association, 2025-06-05
Topic: Risk, prevention and care in population studies
Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiac condition, often caused by mutations in genes encoding desmosomal proteins. The pathologic hallmark of the disease is a fibrofatty replacement of the myocardium, which constitutes the substrate for potentially fatal ventricular arrhythmias. ACM is one of the most common etiology of sudden cardiac death in athletes and young individuals. Although it is well established that regular exercise confers multiple health benefits and better survival in the general population, intense exercise may accelerate the phenotypic expression and the propensity to ventricular arrhythmias in patients with ACM. This review discusses current evidence regarding the safety and the effects of exercise in ACM. We scrutinize research findings based on animal and human models that raise concerns on the possible detrimental role of intense exercise in this condition. Finally, we examine the current knowledge on exercise prescription focusing on the optimal amount of exercise that should be recommended to patients with ACM.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Dei, L., Han, J., Romano, S., Sciarra, L., Asimaki, A., Papadakis, M., et al. (2025). Exercise Prescription in Arrhythmogenic Cardiomyopathy: Finding the Right Balance Between Risks and Benefits. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.039125
Vancouver
Dei L, Han J, Romano S, Sciarra L, Asimaki A, Papadakis M, et al. Exercise Prescription in Arrhythmogenic Cardiomyopathy: Finding the Right Balance Between Risks and Benefits. Journal of the American Heart Association. 2025. doi:10.1161/jaha.124.039125. PMID: 40470644.
BibTeX
@article{dei2025-40470644,
author = {Dei, Lorenzo‐Lupo and Han, Jennie and Romano, Silvio and Sciarra, Luigi and Asimaki, Angeliki and Papadakis, Michael and Sharma, Sanjay and Finocchiaro, Gherardo},
title = {{Exercise Prescription in Arrhythmogenic Cardiomyopathy: Finding the Right Balance Between Risks and Benefits}},
journal = {Journal of the American Heart Association},
year = {2025},
doi = {10.1161/jaha.124.039125},
pmid = {40470644},
url = {https://doi.org/10.1161/jaha.124.039125}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- ACM is one of the most common etiology of sudden cardiac death in athletes and young individuals.
- Although it is well established that regular exercise confers multiple health benefits and better survival in the general population, intense exercise may accelerate the phenotypic expression and the propensity to ventricular arrhythmias in patients with ACM.
- This review discusses current evidence regarding the safety and the effects of exercise in ACM.
- We scrutinize research findings based on animal and human models that raise concerns on the possible detrimental role of intense exercise in this condition.
- Finally, we examine the current knowledge on exercise prescription focusing on the optimal amount of exercise that should be recommended to patients with ACM.
Why it matters
This review is about arrhythmogenic cardiomyopathy, an inherited heart condition, and does not address treating, curing or preventing Alzheimer's disease. It discusses exercise risks and prescription for people with this heart condition.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 44/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 42 of the 96 points we could judge it on, which is 44 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of the American Heart Association) |
| Journal's citation record | 2 / 4 | Journal of the American Heart Association: journal h-index 200 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 18 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 11.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 18 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | 1 / 3 | University of London: institution h-index 804 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40470644) |
| Free to read | 2 / 2 | Free to read |
| Points | 42 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 42 of the 96 points we could judge it on is 44 out of 100. |
| Total | 44 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1161/jaha.124.039125
- PubMed: 40470644
- Original source →
- Free full text: Journal of the American Heart Association →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related studies in Prevention and risk
Also in Prevention and risk
265 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.